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Bone matrix components activate 
the NLRP3 inflammasome and 
promote osteoclast differentiation
Yael Alippe1, Chun Wang1, Biancamaria Ricci2, Jianqiu Xiao1, Chao Qu1, Wei Zou3, Deborah V. 
Novack  1,3, Yousef Abu-Amer2, Roberto Civitelli1 & Gabriel Mbalaviele1
The NLRP3 inflammasome senses a variety of signals referred to as danger associated molecular 
patterns (DAMPs), including those triggered by crystalline particulates or degradation products of 
extracellular matrix. Since some DAMPs confer tissue-specific activation of the inflammasomes, we 
tested the hypothesis that bone matrix components function as DAMPs for the NLRP3 inflammasome 
and regulate osteoclast differentiation. Indeed, bone particles cause exuberant osteoclastogenesis 
in the presence of RANKL, a response that correlates with NLRP3 abundance and the state of 
inflammasome activation. To determine the relevance of these findings to bone homeostasis, we 
studied the impact of Nlrp3 deficiency on bone using pre-clinical mouse models of high bone turnover, 
including estrogen deficiency and sustained exposure to parathyroid hormone or RANKL. Despite 
comparable baseline indices of bone mass, bone loss caused by hormonal or RANKL perturbations is 
significantly reduced in Nlrp3 deficient than in wild type mice. Consistent with the notion that osteolysis 
releases DAMPs from bone matrix, pharmacologic inhibition of bone resorption by zoledronate 
attenuates inflammasome activation in mice. Thus, signals originating from bone matrix activate the 
NLRP3 inflammasome in the osteoclast lineage, and may represent a bone-restricted positive feedback 
mechanism that amplifies bone resorption in pathologic conditions of accelerated bone turnover.
Pathological conditions such as estrogen deficiency and hyperparathyroidism cause high bone turnover, and 
ultimately, a net bone loss, as a result of bone resorption overcoming bone formation over time. Chronic low 
grade inflammation attended by cytokines, including IL-1β and TNF-α, has been linked to bone loss associated 
with estrogen insufficiency1–3. Persistent excessive production of parathyroid hormone (PTH) also causes bone 
loss through mechanisms involving up-regulation of receptor activator of NF-κB ligand (RANKL) expression, the 
obligatory factor for osteoclast-mediated bone resorption4, 5. Indeed, RANKL administration causes massive bone 
resorption6, consistent with the notion that RANKL abundance drives pathological osteolysis. Thus, accelerated 
bone resorption can occur in the absence of high grade inflammation, but the signals that sustain such abnormal 
bone resorption are not known.
The current dogma on bone resorption posits that osteoclasts (OC) acidify the resorption lacuna, resulting 
in the dissolution of the inorganic components of the bone extracellular matrix, including hydroxyapatite7. This 
reaction exposes the organic phase of the bone matrix, which is then degraded by secreted lysosomal enzymes, 
mainly the cysteine protease, cathepsin K7. Evidence also indicates that both the organic and inorganic degrada-
tion products from bone matrix are endocytosed via the OC ruffled membrane8–10. This process enables OC to 
excrete degraded matrix components while digging deep into bone and maintaining an enclosed resorption site. 
Consistent with this concept, collagen I degradation products such as C-telopeptide of type I collagen are found 
in biological fluids and are used as markers of bone resorption11. Thus, bone degradation products should in the-
ory interact with the OC lineage, but whether these materials function as danger-associated molecular patterns 
(DAMPs) and activate the inflammasomes in these cells is not known.
The inflammasomes are intracellular protein complexes expressed mainly by myeloid cells from which the 
osteoclasts arise12. They are assembled by various receptors, including nucleotide-binding oligomerization 
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domain, leucine-rich repeat-containing proteins (NLRP1, NLRP3, NLRP6 and NLRP12), absent in mel-
anoma 2 (AIM 2)-like receptors (ALRs) or pyrin13. These receptors recognize microbial structures known as 
pathogen-associated molecular patterns (PAMPs), and participate in the restoration of tissue integrity after injury 
upon sensing the debris from damaged cells, signals known as danger-associated molecular patterns (DAMPs)13–15. 
Ligand recognition or sensing leads to sequential recruitment of apoptosis-associated speck-like protein con-
taining a CARD (ASC) and pro-caspase-1, which is then converted into active caspase-116, 17. Activated inflam-
masomes are involved primarily in the conversion of pro-IL-1β and pro-IL-18 into biologically active, IL-1β and 
IL-18, respectively13.
The NLRP3 inflammasome is implicated not only in inflammatory disorders18, but also in numerous meta-
bolic diseases driven by low grade inflammation, some of which are caused by specific endogenous components. 
Indeed, the NLRP3 inflammasome is activated by various host DAMPs such as glucose in type-2 diabetes, cho-
lesterol crystals in atherosclerosis and fatty acid in obesity14. More to the point, it was reported recently that loss 
of NLRP3 attenuates osteopenia associated with aging in mice, though the underlying cellular mechanisms were 
not studied in detail19. Thus, whether the NLRP3 inflammasome plays an important role in bone resorption in 
conditions of low grade inflammation, and whether bone matrix components participate in this process remains 
largely unknown.
In this study, we find that bone matrix components promote osteoclastogenesis robustly in WT, but to a lesser 
extent in Nlrp3−/− cells. Importantly, osteopenia caused by high bone turnover is reduced significantly in mutant 
mice compared to WT mice. Moreover, pharmacologic inhibition of bone resorption by zoledronate correlates 
with attenuated inflammasome activation in vivo, suggesting that bone resorption releases the activators of the 
inflammasomes and stimulators of OC differentiation from bone matrix. Thus, the bone DAMPs-NLRP3 inflam-
masome axis may represent a novel mechanism that sustains bone resorption.
Results
Bone matrix components stimulate the expression of inflammasome constituents. Crystalline 
and organic materials are potent activators of the inflammasomes20–23, both of which are released from bone 
extracellular matrix (ECM) during bone resorption, and traffic through bone-resorbing OC8–10. We tested the 
hypothesis that bone degradation products function as DAMPs and regulate the abundance and/or activity of 
the inflammasomes in the OC lineage. The expression of NLRP3 (Fig. 1a and b), Nlrc4 (Fig. 1c) and several other 
components of the inflammasomes (e.g., Nlrp1, Aim2, Asc, caspase-1 or Il-18; Fig. S1) if anything, decreased 
slightly during RANKL-induced OC differentiation of WT or Nlrp3−/− bone marrow macrophages (BMM). In 
contrast, exposure of committed OC precursors (BMM treated with RANKL for 2 days) to bone particles, which 
were prepared by shredding bovine cortical bones, increased Nlrp3 mRNA and protein expression in WT cells 
(Fig. 1a and b). Bone particles also stimulated Nlrc4 (Fig. 1c) and Il-1β (Fig. 1d) mRNA expression in WT and 
Nlrp3−/− cells whereas the abundance of the other inflammasome elements was in general unaffected (Fig. S1a–e). 
To gain insight into the mechanisms through which bone particles regulate the expression of inflammasome 
components, we studied the activation of NF-κB and p38 MAPK, pathways that stimulate the expression of 
pro-inflammatory cytokines24. Phosphorylation of the NF-κB subunit, p65, and p38 MAPK was induced by bone 
particles (Fig. 1e). Phosphorylation of p65 inversely correlated with the abundance of the NF-κB inhibitor, IκBα, 
as expected (Fig. 1e). These results are consistent with the current paradigm that NF-κB is the indispensable 
transducer of the so-called priming signals necessary for pro-IL-1β and NLRP3 induction25, 26.
We also determined whether bone particles can provide secondary signals that assemble functional inflam-
masomes. Inflammasome activation can be monitored by measuring IL-1β secretion or by fluorescence micros-
copy based-detection of cellular foci upon cell incubation with FLICATM FAM-YVAD-FMK probe, which binds 
covalently to active caspase-1. Upon exposure to bone particles, the percentage of cells with active caspase-1 was 
significantly increased in LPS-primed WT BMM compared to Nlrp3−/− BMM (Fig. 2a and b; green foci, white 
arrows). The NLRP3 inflammasome activator, nigericin, used as positive control, induced caspase-1 activity in 
WT, but not Nlrp3−/− BMM as expected (Fig. 2a and b), suggesting that bone particle-dependent residual stain-
ing in mutant cells was caspase-1-independent or reflected the activity of other complexes such as the NLRC4 
inflammasome. Interestingly, similar to nigericin, bone particles also increased IL-1β secretion in LPS-primed 
WT BMM, but not Nlrp3−/− BMM (Fig. 2c). The relatively low concentrations of IL-1β reflect the low cell density, 
which was optimal for the FLICA readout.
Next, we determined whether hydroxyapatite (HA) crystals, the mineral component of bone particles, can 
stimulate the NLRP3 inflammasome. Exposure of LPS-stimulated BMM to synthetic HA crystals induced the 
formation of inflammasome foci (data not shown) and increased IL-1β production in NLRP3-dependent manner 
(Fig. 2d). Collectively, these results indicate that products from bone matrix function as DAMPs and activate the 
NLRP3 inflammasome.
Bone matrix components stimulate OC differentiation. We hypothesized that bone matrix-derived 
products may regulate RANKL-dependent osteoclastogenesis through their positive actions on the NLRP3 
inflammasome, a known stimulator of OC differentiation and activity27, 28. RANKL-induced OC differentia-
tion was not impaired in Nlrp3−/− cells (Fig. 3a and b), consistent with the normal bone mass of mutant mice. 
Interestingly, bone debris enhanced OC formation, a response that was attenuated in Nlrp3−/− cells (Fig. 3a and b; 
Fig. S2a–c), and correlated with IL-1β production (Fig. 3c). Low concentration of RANKL (25 ng/ml) and short 
incubation times (3 days) were used in order to detect synergistic interactions with bone particles. Likewise, HA 
crystals amplified RANKL actions on OC formation in WT cells, but to a lesser extent in mutant cells (Fig. S3a). 
Notably, non-mineralized collagen fragments failed to stimulate OC differentiation (Fig. S3b) and activate the 
NLRP3 inflammasome (data not shown). On the other hand, our studies with demineralized organic phase from 
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bone products were not successful because traces of EDTA, which was used to decalcify bones, remained in the 
decalcified materials and exhibited cytotoxicity (data not shown).
RANKL acts in concert with TNF-α or IL-1β to regulate osteoclastogenesis29, 30. We therefore hypothesized 
that IL-1β released upon exposure to bone particles may subsequently mediate the osteoclastogenic action of 
these materials. Consistent with this prediction, while RANKL-driven OC formation was comparable between 
WT and BMM lacking IL-1 receptor (Il-1r−/−), the effects of bone particles on osteoclastogenesis were blunted 
in mutant cells (Fig. 3d). On the other hand, IL-1β can also affect osteoclastogenesis by up-regulating RANKL 
and M-CSF expression by bone marrow stromal cells (BMSC)31. This raises the possibility that particle-induced 
IL-1β secretion may enhance OC formation through indirect action of this cytokine on BMSC. We investigated 
this scenario by carrying out a co-culture system of BMM and BMSC. Bone particles (Fig. 4a; Fig. S4a) or HA 
crystals (data not shown) induced exuberant osteoclastogenesis, a response that was diminished in BMSC lack-
ing IL-1 receptor. Stimulation of OC formation in WT BMSC and Il-1r−/− BMM co-cultures by bone particles 
may be mediated by other cytokines such as TNF-α, which was also induced by these materials in BMM cultures 
Figure 1. Bone matrix components stimulate the expression of inflammasome constituents. BMM from WT 
or Nlrp3−/− mice were incubated with 50 ng/ml RANKL in the presence of CMG as a source of M-CSF. Cells 
pre-treated with RANKL for 2days (D2) were exposed to bone particles (BP, 125 µg/ml) or PBS for 24 hours 
or 72 hours (h). Cells were harvested on D0 (the first day of RANKL stimulation), D2, D3 or D5 and protein 
and mRNA expression was assessed. (a) Western blot analysis of NLRP3 expression. Data are representative 
of at least 3 independent experiments. Results are from the same gels, but the lanes were cut and pasted (see 
S1f). (b–d) qPCR analysis of mRNA expression. Data are expressed as means ± SD, and are representative of at 
least 3 independent experiments. (b) ****p < 0.0001 (one-way ANOVA and Sidak’s multiple comparison test); 
(c) WT: ***p < 0.0005, Nlrp3−/−: ****p < 0.0001; (d) ****p < 0.0001. (e) Western blot analysis of pathway 
activation. WT BMM were serum-starved overnight and stimulated with 125 µg/ml BP. Cells were harvested at 
the indicated time points.
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(Fig. S4b). Thus, bone DAMPs induce multiple responses, including NLRP3 inflammasome-mediated maturation 
of IL-1β, which promotes osteoclastogenesis by acting directly on BMM, and indirectly via BMSC.
Osteopenia associated with high bone turnover is reduced in mice lacking NLRP3. Since IL-1β 
has been shown to mediate the effects of estrogen deficiency on bone1–3, we hypothesized that the NLRP3 inflam-
masome, via maturation of IL-1β plays a role in estrogen-dependent osteopenia. We therefore studied the effect 
of ovariectomy (OVX) on bone mass in Nlrp3 deficiency, a low-grade inflammation model. Baseline femoral bone 
mass shown as volumetric trabecular bone volume/tissue volume (BV/TV) was comparable between 4-month old 
WT and Nlrp3-deficient female mice based on viva-computed tomography (vivaCT) analysis (data not shown), 
confirming that NLRP3 is dispensable for bone homeostasis in young adult mice19. The analysis performed 8 
weeks after surgery revealed significantly reduced BV/TV in WT OVX mice compared to sham-operated 
mice (Fig. 5a). In contrast, bone parameters were not statistically different between OVX and sham-operated 
Figure 2. Bone matrix components provide secondary signals that assemble functional inflammasomes. 
WT or Nlrp3−/− BMM were incubated for 3 hours with 100 ng/ml LPS and stimulated with 15 µM nigericin 
for 30 minutes, bone particles (BP, 1.25–5 mg/ml) or hydroxyapatite (HA) crystals (0.25–1 mM) for 1 hour. 
(a) Cells were then incubated with FLICATM FAM-YVAD-FMK probe and analyzed by fluorescence 
microscopy. Original magnification, 20x; scale bars = 10 µm; white arrows show foci of caspase-1 activation. (b) 
Quantification of FLICA+ cells. Data are means ± SD of at least 3 fields. (c,d) IL-1β release in the conditioned 
media. Data are means ± SD from experimental triplicates, and are representative of at least 2 independent 
experiments. (b) **p = 0.0062, ***p = 0.0003, ****p < 0.0001; (c) ***p = 0.0008, ****p < 0.0001. p values 
correspond to significant differences relative to the control for each genotype.
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Nlrp3−/− mice (Fig. 5a), suggesting that NLRP3 deficiency protects mice from the excessive bone loss associated 
with estrogen insufficiency.
PTH stimulates bone resorption via up-regulation of RANKL in osteoblasts and osteocytes5. We therefore 
tested whether the NLRP3 inflammasome is involved in bone resorption driven by PTH. While in WT continu-
ous PTH infusion (80 µg/kg, for 2 weeks) caused 25% loss of BV/TV (~15% larger than in vehicle-treated mice; 
Fig. 5b), only less than 10% decrease in BV/TV was observed in Nlrp3−/− mice treated with PTH, similar to 
vehicle-treated groups (Fig. 5b), indicating that lack of Nlrp3 protects from PTH induced bone loss.
To test whether the NLRP3 inflammasome mediates RANKL effect on bone, mice were given RANKL (1 µg/
kg, daily for 2 days) intraperitoneally, an acute regimen that causes substantial bone resorption6. As mentioned 
above, there was no difference in BV/TV between WT and Nlrp3−/− mice at baseline (Fig. 5c). In contrast, 
RANKL caused approximately 6% loss of BV/TV in WT, but not Nlrp3-ablated mice (Fig. 5c). These data are in 
agreement with the view that the inflammasomes are active mainly in innate immune cells32, as RANKL triggers 
bone resorption through its action on myeloid cell subsets. Thus, despite the inconsistency we noticed related 
to changes in bone mineral density (BMD), the number (Tb.N) and thickness (Tb.Th) of the trabeculae, and 
trabecular space (Tb.Sp) (Fig. S5), collectively, our data indicate that the NLRP3 inflammasome promotes bone 
resorption in various states of accelerated bone turnover such as estrogen deficiency and sustained exposure to 
PTH or RANKL.
The inflammasomes are activated in the bone environment in response to signal released 
during bone resorption. The FLICATM FAM-YVAD-FMK probe can also be used for flow cytometry to 
assess the state of inflammasome activation28. By this method, the percentage of FLICA+ mononucleated cells at 
Figure 3. Bone matrix components stimulate OC differentiation. BMM from WT or Nlrp3−/− mice were 
incubated with 25 ng/ml RANKL for 2 days (D2) then treated with bone particles. (a) Cells were stained for 
TRAP on day 3 (D3). Original magnification, ×2. (b) OC number/well. (c) IL-1β production was measured 
in the supernatants from (b). (d) Effects of IL-1 receptor deficiency on OC formation. Experiments were run 
in triplicates, and data are means ± SD. (b) **p = 0.0013, ****p < 0.0001; (c) WT: ****p < 0.0001; Nlrp3−/−: 
**p = 0.0030, ****p < 0.0001; (d) ***p = 0.0008; ****p < 0.0001. p values correspond to significant differences 
relative to the control for each genotype, and data are representative of at least 4 independent experiments.
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Figure 4. Bone matrix components induce OC formation in co-cultures. BMSC and BMM were obtained from 
WT or Il-1r−/− mice, and the co-cultures were set up for various cell combinations at a 1:1 ratio. After 2 days of 
co-cultures, bone particles (BP) were added and TRAP staining was performed at day 4 (a), and OC number 
was determined by counting multinucleated, TRAP-positive cells (b). **p = 0.0084, ***p = 0.0004. Data are 
means ± SD of samples run in triplicates, and are representative of at least 2 independent experiments. p values 
correspond to significant differences relative to WT BMSC:WT BMM (control).
Figure 5. Osteopenia associated with high bone turnover is reduced in mice lacking NLRP3. (a) VivaCT 
analysis was performed on the femurs of 4-month old WT and Nlrp3−/− female mice before and at 8 weeks after 
OVX or sham surgery. (b) VivaCT analysis of 4-month old WT and Nlrp3−/− male mice exposed to PTH (80 μg/
kg/day) or vehicle for 2 weeks via osmotic pumps. Data are means ± SD of the percentage of changes relative to 
baseline (before surgery or treatment) of 4–6 mice/group; (a) *p = 0.0111; (b) **p = 0.0017. (c) Post-mortem 
µCT scan was performed on the femurs from 3-month old WT and Nlrp3−/− male mice exposed to acute 
RANKL treatment (1 µg/kg once a day, for 2 days). Data are means ± SD of 4–7 mice/group; **p = 0.0062.
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baseline was similar in 3-month-old WT and Nlrp3−/−mice (Fig. 6a). Administration of RANKL increased the 
percentage of FLICA+ cells in WT mice, but not Nlrp3−/− mice (Fig. 6a). RANKL injection also increased IL-1β 
production in WT (Fig. 6b). In contrast, the cytokine had no noticeable effect on IL-1β secretion in Nlrp3-ablated 
mice (Fig. 6b). It has been recently reported that RANKL induced IL-1β production by the OC lineage33. Thus, 
the inflammasomes including those nucleated by NLRP3 may be involved in bone resorption. We therefore 
determined whether inhibition of bone resorption by zoledronic acid, a potent bisphosphonate, would alter 
RANKL-induced bone loss and inflammasome activation in 3-month-old WT male mice. In mice treated with 
vehicle, RANKL administration induced approximately 10% bone mass loss, and pre-treatment with zoledronate 
prevented such loss (Fig. 6c and d), results that correlated with microstructural trabecular parameters (Fig. S6). 
Notably, zoledronate-treated mice had higher bone mass than vehicle-treated animals, also an expected finding 
(Fig. 6c and d; Fig. S6). Zoledronate had no effects on the percentage of FLICA+ cells at baseline or in response 
to RANKL treatment (Fig. 6e). These results were unexpected, but may be explained by the fact that accurate 
determinations of intracellular caspase-1 in vivo is challenging because caspase-1 is also secreted25, 34. We there-
fore analyzed IL-1β production. We found that zoledronate prevented RANKL-induced increase of IL-1β in bone 
marrow (Fig. 6f). Taken together with our in vitro data showing that bone particles failed to cause IL-1β produc-
tion in Nlrp3−/− BMM (Fig. 2), we propose that signals released during bone degradation cause inflammasome 
activation to sustain bone resorption (Fig. S7).
Discussion
Auto-inflammatory disorders such as neonatal-onset multisystem inflammatory disease (NOMID) are caused 
by NLRP3-activating mutations, and are associated with osteopenia35, 36. The bone outcome is the consequence 
of chronic inflammatory osteolysis27 and is consistent with the central role of this inflammasome in the matu-
ration of IL-1β, a pro-osteoclastogenic cytokine whose levels are markedly elevated in NOMID27, 37. While it is 
Figure 6. The inflammasomes are activated in the bone environment in response to cues released during 
bone resorption. RANKL was administrated (1 µg/kg, daily, for 2 days) to WT or Nlrp3−/− 3-month old male 
mice. (a) Percentage of FLICA+ cells in whole bone marrow cells determined by flow cytometry (n = 5–7 mice/
group); *p = 0.0225. (b) IL-1β production in bone marrow (n = 6–16 mice/group); *p = 0.0126 (multiple t-test 
and Holm-Sidak). (c and d) WT 3-month old mice were given 40 µg/kg zoledronate or PBS once a week for 4 
weeks before RANKL treatment (n = 5 mice/group). Bones were analyzed by µCT. BV/TV: *p = 0.0274; BMD: 
*p = 0.0351. (e) FLICA+ bone marrow cells (n = 5 mice/group). *p = 0.0275 for the PBS group; *p = 0.0408 for 
the zoledronate group. (f) IL-1β release in bone marrow (n = 5 mice/group). *p = 0.0286.
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established that mutated NLRP3 produces pathogenic effects to bone, little is known regarding the role that WT 
NLRP3 plays in this tissue. Here, we find that lack of NLRP3 abrogates in vitro osteoclastogenesis induced by 
bone particles, and more importantly, attenuates bone loss in mouse models of post-menopausal osteoporosis 
and hyperparathyroidism. Others have reported the bone-protective effects of NLRP3-deficiency in age-related 
osteopenia in mice19. Thus, the NLRP3 inflammasome has far-reaching actions in bone homeostasis than origi-
nally thought, acting not only in the context of severe inflammation, but also in states of low grade inflammation 
(e.g., estrogen deficiency or aging). The premise that NLRP3 functions downstream of RANKL signaling is in 
agreement with our previous work demonstrating that genetic activation of NLRP3 in the OC lineage causes bone 
resorption in the absence of inflammation28. On the other hand, the normal bone phenotype of Nlrp3 null mice at 
baseline suggests that other inflammasomes such as those assembled by NLRC4 are also involved in homeostatic 
bone remodeling and that the NLRP3 inflammasome is more important in pathological osteolytic states.
The NLRP3 inflammasome is activated in response to various stresses, including those triggered by accidental 
release of lysosomal contents in the cytosol upon rupture of particulate-containing phagolysosomes, excessive 
levels of mitochondrial-derived reactive oxygen species and K+ efflux12. Our findings indicating that inflammas-
ome activation in mice is attenuated upon administration of zoledronate imply that this drug inhibits not only 
bone resorption, but also the release of DAMPs from bone matrix. Potential bone relevant DAMPs include bone 
degradation products, which have been shown to traffic through the OC, though the impact of the transcytosis 
process on OC’s function remains unknown. Bone particles and synthetic hydroxyapatite crystals are used as sur-
rogates of bone degradation products and have been shown to modulate numerous bone cell responses, including 
the differentiation of OC and enhancement of cathepsin K secretion by these cells38, 39. Here, we show that bone 
matrix-derived products also activate the NLRP3 inflammasome and stimulate OC formation. However, the pos-
sibility that zoledronate inhibits OC directly through GTPase prenylation40 independently of the inflammasome 
mechanism cannot be ruled out.
Bone particles not only promote the assembly of the inflammasomes, but also stimulate NLRP3, NLRC4 
and IL-1β mRNA expression, suggesting that they provide both the priming and secondary signals. Oxidized 
low-density lipoprotein and hyaluronan have also been shown to generate both types of inputs to the inflam-
masomes41–43. Although we ruled out any contaminations of bone DAMPs by LPS (data not shown), bone debris 
remain heterogeneous materials comprising mineral and organic components of different sizes and shapes. As 
a result, elements of these mixtures may affect distinct steps of the inflammasome activation process. However, 
our findings indicating that hydroxyapatite crystals, but not non-mineralized type 1 collagen fragments activate 
the NLRP3 inflammasome suggest dominant actions of the mineral phase of bone particles in inflammasome 
activation. This view is consistent with reports indicating that basic calcium phosphate crystals, which include 
hydroxyapatite crystals, are potent activators of the NLRP3 inflammasome44. Future studies are still needed to 
determine whether the mineral phase of bone DAMPs acts as particulates or as a source of Ca2+. This is important 
because Ca2+ fluxes also activate this inflammasome45.
Bone matrix components stimulate IL-1β production in cell cultures, and loss of IL-1 receptor reduces the 
effects of these particles on osteoclastogenesis, suggesting autocrine and/or paracrine actions of this cytokine 
in this process. On the other hand, IL-1β release, not the caspase-1 activity readout consistently correlates with 
NLRP3 inflammasome activation in mice; the reasons for this disparity remain unclear. More to the point, the 
ability of bone particles to induce IL-1β production and our reliance on IL-1β secretion as readout of inflammas-
ome activation in vivo are seemingly at odds with the concept that WT NLRP3 inflammasome can mediate bone 
resorption in non-inflammatory conditions. We contend that the doses of bone particles or RANKL that we used 
are exaggerated, but justified in order to inflict cellular perturbations and detect biological changes, including 
IL-1β secretion. Even if the inflammasome-mediated IL-1β release is enhanced by bone degradation products 
during bone resorption in vivo, such responses likely reflect low grade inflammation tailored to promote bone 
homeostasis, not to cause disease.
This work introduces a novel concept in bone biology postulating that products originating from bone matrix 
activate the NLRP3 inflammasome, thus functioning as a positive feedback loop that amplifies bone resorption 
(Fig. S7). Thus, the bone-protective action of NLRP3 deficiency in various animal models of accelerated bone 
turnover positions this inflammasome as a target for therapeutic intervention, not only for inflammatory disor-
ders, but also bone metabolic diseases.
Materials and Methods
Animals and in vivo experiments. Il-1 receptor deficient (Il-1r−/−) mice and Nlrp3 null (Nlrp3−/−) mice 
were purchased from Jackson Laboratory. All mice were on C57BL6 background, and mouse genotyping was 
performed by PCR. To induce estrogen deficiency, bilateral ovariectomy (OVX) or sham surgery (in which ova-
ries were exteriorized, but replaced intact) were performed under general anesthesia in 4-month old WT or 
Nlrp3−/− mice, and bones were analyzed 8 weeks after surgery. Estrogen deficiency was confirmed by uterine 
atrophy. For PTH experiments, 80 μg/kg/day human PTH1-34 or vehicle were delivered to 4-month old WT or 
Nlrp3−/− male mice for 2 weeks via subcutaneously implanted ALZET osmotic pumps (model-1002, DURECT 
Corporation) with a delivery rate of 0.25 ml/h as previously described46. GST-RANKL or vehicle was adminis-
trated intra-peritonally to 3-month old WT or Nlrp3−/− male mice at a dose of 1 µg/kg, daily for 2 days. For phar-
macologic inhibition of bone resorption, 40 mg/kg zoledronate (Novartis #484188) were injected subcutaneously 
to 3-month old WT mice, once a week, for 4 weeks prior to GST-RANKL injection. All procedures were approved 
by the Institutional Animal Care and Use Committee of Washington University School of Medicine in St. Louis. 
All experiments were performed in accordance with the relevant guidelines and regulations described in the 
IACUC-approved protocol #20160245.
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Bone mass and microstructure. Micro-computerized tomography (CT) scanning was performed in vivo 
(Scanco VivaCT40) on each animal before and after surgery or PTH administration as previously described47. 
Post mortem micro-computed tomography (µCT) system (Scanco uCT40) was performed for the evaluation of 
bone parameters 2 days after GST-RANKL administration. Briefly, femora from mice were stabilized in 2% aga-
rose gel, and µCT scans were taken along the length of the femur as previously described48.
Preparation of bone particles. Bone particles were prepared by shredding bovine cortical bones with 
an automatic low speed saw (Buehler IsoMet). Particles were washed with 70% ethanol, resuspended in PBS, 
autoclaved, and washed 3 more times with PBS before the weight of dried bone particles was determined. 
Hydroxyapatite (HA) crystals were purchased from Sigma (677418, particle size <200 nm) and stock solutions in 
PBS were exposed to UV light before use. Collagen I was purchased from Santa Cruz Biotechnology (sc-29009), 
sonicated 2 times for 5 seconds each with the amplitude set at 40 (Sonics Vibracell VC130BP) and filtered with a 
0.22 µm syringe filter.
Cell isolation and cultures. Bone marrow (BM) cells were eluted from femurs and tibias as previously 
described48. BM macrophages (BMM) were obtained by culturing BM cells for 5 days in culture media containing 
a 1:25 dilution of supernatant from CMG 14-12 cells (CMG 14-12), as a source of macrophage colony-stimulating 
factor (M-CSF) as previously described49 or with recombinant M-CSF (BioLegend). To induce OC differentia-
tion, non-adherent cells were removed by vigorous washes with PBS, and adherent BMM were detached with 
Trypsin-EDTA and plated at 0.5–1 × 104 cells/well in a 96-well plate in culture media containing a 1:50 dilution 
of CMG. To induce OC differentiation, BMM were treated with 25–50 ng/ml receptor activator of NF-kB ligand 
(RANKL) on the next day after plating (D0). Bone particles or HA crystals were added on day 2 (D2) of the cul-
tures, which were fed every 2 days afterwards as previously described48 and maintained at 37 °C in a humidified 
atmosphere of 5% CO2 in air.
For co-culture experiments, bone marrow stromal cells (BMSC) were obtained by culturing BM cells 
in α-MEM containing 20% fetal bovine serum (Invitrogen) as previously described50. Upon confluence, 
non-adherent cells were removed by vigorous washes with PBS, and adherent BMSC were detached with 
trypsin-EDTA. Co-cultures were prepared by plating BMSC and BMM at a 1:1 ratio (4.5–6 × 104 total cells/well in 
96-well plate) in medium containing 10 nM 1,25(OH)2D3 and 100 nM dexamethasone as previously described50. 
BP or HA crystals were added 2 days after the initiation of the co-cultures.
TRAP assay. Cytochemical staining for TRAP was used to identify OC as previously described48. Briefly, 
cells in a 96-well plate were fixed with 3.7% formaldehyde and 0.1% Triton X-100 for 10 min at room temperature. 
Cells were rinsed with water and incubated with the TRAP staining solution (Sigma leukocyte acid phosphatase 
kit) at room temperature for 30 minutes. Multinucleated TRAP-positive cells with ≥3 nuclei were scored as OC 
under light microscopy. Samples were analyzed with an inverted Nikon Eclipse Ti-U microscope and pictures 
were taken by using a coupled QImaging digital camera and MetaMorph software.
mRNA expression analysis. Total RNA was harvested from cultured OC grown in 6-well plates using 
PureLink RNA Mini Kit (Invitrogen). Complementary DNA was then synthesized with the High Capacity cDNA 
kit (AppliedBiosystems). Gene expression was analyzed using the primers listed in Supplemental Table 1 with 
Terra qPCR direct SYBR Green Premix (Takara, Clontech). qPCR was performed in the QuantStudio3 cycler 
(AppliedBiosystems) and the results were analyzed by using the ΔΔCT method normalizing against cyclophilin B.
Analysis of caspase-1 activity by flow cytometry. Mouse BM cells were obtained as described above. 
Red blood cells were depleted with red blood cell lysis buffer (Roche). Cells at 0.5–1 × 106/ml were incubated 
with the FLICATM FAM-YVAD-FMK probe (ImmunoChemistry Technology LLC, 97) for 30 minutes at 37 °C, 
washed and fixed in 10% buffered formalin according to the supplier’s instructions. Samples were acquired with a 
FACSCalibur (BD) in the FL-1 channel, followed by analysis with FlowJo software (Tree Star, Inc.).
Microscopic detection of caspase-1 activity. BMM were plated at 5 × 104 cells per well on a 96-well 
plate and maintained for 24 h in culture media containing a 1:10 dilution of CMG. Cells were primed with 100 ng/
ml LPS for 3 hours and incubated with 15 µM nigericin (positive control) for 30 minutes or BP (1.25–5 mg/ml) or 
HA crystals (0.25–1 mM) for 1 hour. Cells were incubated with the FLICATM FAM-YVAD-FMK probe as recom-
mended by the supplier (30 minutes at 37 °C, 2 washes with PBS/FBS and fixation with 10% buffered formalin. 
Cells were then counterstained with Fluoro-gel II containing DAPI (Electron Microscopy Sciences). Images were 
taken with a DP70 Olympus Digital Camera coupled to an IX51Olympus inverted microscope, captured with 
QCapture Pro software and analyzed with ImageJ software.
Western blot analysis. Cell extracts were prepared by lysing cells cultured in 6-well plates with RIPA buffer 
(50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% NaDOAc, 0.1% SDS, and 1.0%NP-40) plus phosphatase and 
protease inhibitor cocktails (Xpert P3200-001 and P3100-001, respectively, GenDEPOT). Protein concentrations 
were determined by the Bio-Rad method (DC Protein Assay), and equal amounts of proteins were subjected to 
SDS-PAGE gels (8–15%). Proteins were transferred onto PVDF membranes and incubated with primary antibody 
overnight at 4 °C, followed by a 1 h incubation with secondary goat anti-mouse or goat anti-rabbit Alexa-Fluor 
680 (Molecular Probes), or donkey anti-goat 780 (LI-COR Biosciences). Primary antibodies include NLRP3 
antibody (Adipogen), phospho-p65 antibody, IκB antibody, total p65 antibody and phospho-p38 antibody (Cell 
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Signaling Technology), total p38 antibody and β-actin antibody (Santa Cruz Biotechnology). The results were 
visualized using Li-Cor Odyssey Infrared Imaging System (LI-COR Biosciences).
Immunoassays. IL-1β levels in bone marrow or cell culture supernatants were determined by ELISA (eBio-
science) as previously described27, 28.
Statistical analysis. Statistical significance was assessed by 2-way ANOVA, unless otherwise stated, fol-
lowed by an appropriate multiple comparison test (Sidak’s, Dunnett’s, Fisher’s LSD or Tukey’s) using the GraphPad 
Prism 6 software.
References
 1. Kitazawa, R., Kimble, R. B., Vannice, J. L., Kung, V. T. & Pacifici, R. Interleukin-1 receptor antagonist and tumor necrosis factor 
binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94, 2397–2406 (1994).
 2. Pacifici, R. et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. 
Acad. Sci. 86, 2398–2402 (1989).
 3. Cioffi, M. et al. Cytokine pattern in postmenopause. Maturitas 41, 187–192 (2002).
 4. Dai, J. C., He, P., Chen, X. & Greenfield, E. M. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression 
with markedly different kinetics. Bone 38, 509–520 (2006).
 5. Xiong, J. & O’Brien, C. A. Osteocyte RANKL: New insights into the control of bone remodeling. J. Bone Miner. Res. 27, 499–505 
(2012).
 6. Novack, D. V. et al. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198, 771–781 
(2003).
 7. Novack, D. V. & Mbalaviele, G. Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol. Spectrum 4 (2016).
 8. Nesbitt, S. A. & Horton, M. A. Trafficking of Matrix Collagens Through Bone-Resorbing Osteoclasts. Science 276, 266–269 (1997).
 9. Salo, J., Lehenkari, P., Mulari, M., Metsikkö, K. & Väänänen, H. K. Removal of Osteoclast Bone Resorption Products by Transcytosis. 
Science 276, 270–273 (1997).
 10. Leung, P., Pickarski, M., Zhuo, Y., Masarachia, P. J. & Duong, L. T. The effects of the cathepsin K inhibitor odanacatib on osteoclastic 
bone resorption and vesicular trafficking. Bone 49, 623–635 (2011).
 11. Kawana, K., Takahashi, M., Hoshino, H. & Kushida, K. Comparison of serum and urinary C-terminal telopeptide of type I collagen 
in aging, menopause and osteoporosis. Clin. Chim. Acta 316, 109–115 (2002).
 12. Schroder, K. & Tschopp, J. The Inflammasomes. Cell 140, 821–832 (2010).
 13. Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nature Med. 21, 
677–687 (2015).
 14. Lukens, J. R., Gross, J. M. & Kanneganti, T. D. IL-1 family cytokines trigger sterile inflammatory disease. Frontiers Immunol. 3, 315 
(2012).
 15. Martin, S. J. Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system. FEBS 
J. 283, 2599–2615 (2016).
 16. Cerretti, D. P. et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 256, 97–100 (1992).
 17. Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 
356, 768–774 (1992).
 18. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror Autoinflammaticus: The Molecular Pathophysiology of 
Autoinflammatory Disease*. Ann. Rev. Immunol. 27, 621–668 (2009).
 19. Youm, Y. H. et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 
18, 519–532 (2013).
 20. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. 
Nature 440, 237–241 (2006).
 21. Cobelli, N., Scharf, B., Crisi, G. M., Hardin, J. & Santambrogio, L. Mediators of the inflammatory response to joint replacement 
devices. Nat. Rev. Rheumatol. 7, 600–608 (2011).
 22. Anderson, H. C., Mulhall, D. & Garimella, R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, 
including cancer, renal diseases, atherosclerosis, and arthritis. Lab. Invest. 90, 1549–1557 (2010).
 23. Burton, L. et al. Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation. 
J. Orthop. Res. 31, 73–80 (2013).
 24. Mbalaviele, G. et al. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to 
the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. J. 
Pharm. Exp. Therap. 329, 14–25 (2009).
 25. Bauernfeind, F. G. et al. Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 
Inflammasome Activation by Regulating NLRP3 Expression. J. Immunol. 183, 787–791 (2009).
 26. Segovia, J. et al. TLR2/MyD88/NF-kappaB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome 
during respiratory syncytial virus infection. PloS One 7, e29695 (2012).
 27. Bonar, S. L. et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. 
PloS One 7, e35979 (2012).
 28. Qu, C. et al. NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms. FASEB J. 29, 1269–1279 
(2015).
 29. Lam, J. et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK 
ligand. J. Clin. Invest. 106, 1481–1488 (2000).
 30. Ma, T. et al. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. 
Cytokine 26, 138–144 (2004).
 31. Quinn, J. M., Horwood, N. J., Elliott, J., Gillespie, M. T. & Martin, T. J. Fibroblastic stromal cells express receptor activator of NF-
kappa B ligand and support osteoclast differentiation. J. Bone Min. Res. 15, 1459–1466 (2000).
 32. Brydges, S. D. et al. Inflammasome-Mediated Disease Animal Models Reveal Roles for Innate but Not Adaptive Immunity. Immunity 
30, 875–887 (2009).
 33. Kim, H. et al. The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. Sci. 
Rep. 7, 196 (2017).
 34. Baroja-Mazo, A. et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. 
Nature immunology 15, 738–748 (2014).
 35. Hill, S. et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediat. Radiol. 37, 145–152 
(2007).
 36. Snouwaert, J. N. et al. An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice. Cell Rep. 17, 3077–3088 
(2016).
www.nature.com/scientificreports/
1 1ScIentIfIc REPORts | 7: 6630  | DOI:10.1038/s41598-017-07014-0
 37. Hoffman, H. M. & Brydges, S. D. Genetic and Molecular Basis of Inflammasome-mediated Disease. J. Biol. Chem. 286, 10889–10896 
(2011).
 38. Cremasco, V. et al. Protein kinase C-delta deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and 
ruffled border formation in osteoclasts. J. Bone Miner. Res. 27, 2452–2463 (2012).
 39. Chang, C. C., Tsai, Y. H., Liu, Y., Lin, S. Y. & Liang, Y. C. Calcium-containing crystals enhance receptor activator of nuclear factor 
kappaB ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 
pathways. Rheumatol. 54, 1913–1922 (2015).
 40. Russell, R. G. Bisphosphonates: the first 40 years. Bone 49, 2–19 (2011).
 41. Yamasaki, K. et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous 
trigger of inflammation in response to injury. J. Biol. Chem. 284, 12762–12771 (2009).
 42. Schaefer, L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 289, 35237–35245 
(2014).
 43. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 
(2010).
 44. Pazar, B. et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1beta secretion through the NLRP3 
inflammasome in vitro. J. Immunol. 186, 2495–2502 (2011).
 45. He, Y., Hara, H. & Nunez, G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem. Sci. 41, 1012–1021 
(2016).
 46. Gao, Y. et al. T Cells Potentiate PTH-Induced Cortical Bone Loss through CD40L Signaling. Cell Metab. 8, 132–145 (2008).
 47. Laperre, K. et al. Development of micro-CT protocols for in vivo follow-up of mouse bone architecture without major radiation side 
effects. Bone 49, 613–622 (2011).
 48. Wang, C. et al. Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast 
maturation. Cell Death & Dis. 7, e2153 (2016).
 49. Takeshita, S., Kaji, K. & Kudo, A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes 
being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1477–1488 (2000).
 50. Watkins, M. et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol. Biol. Cell 
22, 1240–1251 (2011).
Acknowledgements
We thank Dr. Katherine Weilbaecher for providing zoledronate. We also thank Washington University 
Musculoskeletal Research Center, NIH/NIAMS P30 AR057235. This work was supported by NIH/NIAMS 
AR064755 and AR068972 grants to G.M. Y.A-A. is supported by AR049192 and AR054326 grants.
Author Contributions
Y.A., C.W., B.R., J.Q., C.Q. and W.Z. performed research; Y.A., C.W., J.Q. reviewed the data; D.V.N., Y.A-A., and 
R.C. contributed new reagents and reviewed the paper; G.M. designed research and wrote the paper.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07014-0
Competing Interests: G.M. is co-founder of Confluence Life Sciences. R.C. receives research support from 
Pfizer, Inc. and Amgen, and holds stock of Amgen, Eli-Lilly and Merck & Co. They have no additional financial 
interests. All other authors declare no competing financial interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
